Lazard Asset Management
MYGN icon

Lazard Asset Management’s Myriad Genetics MYGN Stock Holding History

Lazard Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,670
Closed -$106K – 1982
2025
Q3 		$106K Buy
+14,670
New +$87.1K ﹤0.01% 1680
2025
Q2 		– Sell
-4,136
Closed -$36K – 2455
2025
Q1 		$36K Sell
4,136
-68,031
-94% -$817K ﹤0.01% 2050
2024
Q4 		$989K Buy
72,167
+7,614
+12% +$140K ﹤0.01% 1155
2024
Q3 		$1.77M Buy
64,553
+26,904
+71% +$728K ﹤0.01% 900
2024
Q2 		$920K Buy
37,649
+16,506
+78% +$362K ﹤0.01% 991
2024
Q1 		$449K Buy
21,143
+9,036
+75% +$194K ﹤0.01% 1079
2023
Q4 		$231K Buy
12,107
+164
+1% +$2.84K ﹤0.01% 1337
2023
Q3 		$191K Buy
11,943
+7,268
+155% +$138K ﹤0.01% 1401
2023
Q2 		$107K Buy
4,675
+1,925
+70% +$42K ﹤0.01% 1557
2023
Q1 		$63K Buy
2,750
+1,514
+122% +$30.7K ﹤0.01% 1720
2022
Q4 		$17K Hold
1,236
– – ﹤0.01% 2153
2022
Q3 		$23K Buy
+1,236
New +$28.4K ﹤0.01% 2068
2021
Q3 		– Sell
-1,774
Closed -$54K – 2241
2021
Q2 		$54K Buy
+1,774
New +$51.3K ﹤0.01% 1567
2019
Q4 		– Sell
-521
Closed -$14K – 1614
2019
Q3 		$14K Buy
+521
New +$15.2K ﹤0.01% 1185

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lazard Asset Management's MYGN Position: Q4 2025 in Review

Lazard Asset Management sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 14,670 shares — an estimated $106K sold.

Lazard Asset Management first reported a position in MYGN in Q3 2019 and held it in 14 quarters. The position peaked at $1.77M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Lazard Asset Management reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Lazard Asset Management sold 14,670 Myriad Genetics shares in Q4 2025, an estimated $106K.
  • Lazard Asset Management first reported a position in Myriad Genetics in Q3 2019 and held it in 14 quarters.
  • Lazard Asset Management's Myriad Genetics position peaked at $1.77M in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.